<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163914">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00964236</url>
  </required_header>
  <id_info>
    <org_study_id>PKU/Kuvan/Christ</org_study_id>
    <nct_id>NCT00964236</nct_id>
  </id_info>
  <brief_title>The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)</brief_title>
  <official_title>The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to determine whether Kuvan™ (sapropterin) improves the
      strength of the functional connectivity between brain regions in individuals with PKU.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is designed to evaluate the hypothesis that functional connectivity may
      represent an early marker for neurocognitive improvements related to Kuvan treatment. As a
      first step in the study, 20 patients with PKU who are ≥ 6 years of age will receive baseline
      functional connectivity magnetic resonance imaging (fcMRI) evaluations before being treated
      with Kuvan™. Response to Kuvan™ will be monitored for 4 weeks. At the end of 4 weeks,
      response to Kuvan™ will be reviewed and all 20 patients will receive follow-up fcMRI
      evaluations. Fifteen patients with a reduction of ≥ 20% in blood phenylalanine will continue
      in the study and receive a third fcMRI evaluation at the end of 6 months of treatment with
      Kuvan™. For comparison purposes and to control for possible practice effects in repeated
      testing, a matched control group of 20 healthy individuals without PKU will used. All 20 of
      the control subjects will receive baseline and 4-week fcMRI evaluations; fifteen will
      receive a 6-month evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>functional magnetic resonance imaging of the brain</measure>
    <time_frame>baseline, 4 week, &amp; 6 month follow-up</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Phenylketonuria</condition>
  <arm_group>
    <arm_group_label>Sapropterin</arm_group_label>
    <description>Individuals with phenylketonuria (PKU) who are beginning treatment with Kuvan (sapropterin).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy individuals without phenylketonuria (PKU).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sapropterin</intervention_name>
    <description>Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.</description>
    <arm_group_label>Sapropterin</arm_group_label>
    <other_name>Kuvan</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic for phenylketonuria. Columbia, Missouri, community for control.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide informed consent or assent.

          -  Willing and able to comply with study procedures.

          -  Greater than or equal to 6 years of age.

          -  For phenylketonuria, intention of physician to prescribe sapropterin.

          -  For phenylketonuria, phenylalanine level greater than or equal to 300μmol/L.

          -  For phenylketonuria, negative pregnancy test if of childbearing potential.

          -  For phenylketonuria, willing to use contraception if sexually active.

        Exclusion Criteria:

          -  Pregnant, breastfeeding, or planning to become pregnant during study.

          -  Use of investigational product less than 30 days prior to or during study.

          -  Concurrent condition that could interfere with participation or safety.

          -  Any condition creating high risk of poor compliance with study.

          -  Perceived to be unreliable or unavailable for study.

          -  Use of L-Dopa, methotrexate, or other drugs that inhibit folate metabolism.

          -  For phenylketonuria, known hypersensitivity to sapropterin or excipients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shawn E Christ, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri-Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Christ SE, Steiner RD, Grange DK, Abrams RA, White DA. Inhibitory control in children with phenylketonuria. Dev Neuropsychol. 2006;30(3):845-64.</citation>
    <PMID>17083296</PMID>
  </reference>
  <reference>
    <citation>Araujo GC, Christ SE, Steiner RD, Grange DK, Nardos B, McKinstry RC, White DA. Response monitoring in children with phenylketonuria. Neuropsychology. 2009 Jan;23(1):130-4. doi: 10.1037/a0013488.</citation>
    <PMID>19210041</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 21, 2016</lastchanged_date>
  <firstreceived_date>August 21, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sapropterin</keyword>
  <keyword>Kuvan</keyword>
  <keyword>cognition</keyword>
  <keyword>brain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Verapamil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
